The success of the unique
analytical approach brought to microRNA (miRNA) profiling technologies by
Scottish-based, Sistemic Ltd., (Glasgow, UK) has led to sustained interest from
the drug discovery and cell therapeutics markets. As a result the company has
commenced an expansion programme which will see the addition of a number of key
scientific and bioinformatic staff and a move to a larger dedicated facility
near Glasgow, which will also form the company's new global headquarters.
This will enable Sistemic to fulfil current contracts more rapidly as well as
providing further capacity for newly acquired and future contracts. It will
also support the company's expansion of its key internal R&D programmes in
drug toxicology and stem cell characterisation.
The expansion programme will also see the company grow its US
commercial operations developing its Boston location and opening an office in
California. Commenting on the programme Mr Jim Reid, Sistemic Chairman and CEO
said "We are delighted that things are going so well for the company
especially when so many businesses are downsizing or finding life tough. It is
a real endorsement of the unique technology we are developing and the
customer-centric approach we take to our business." Dr Verna McErlane, Director
of Commercial Operations,
added; "We are committed to global expansion and see the developments in
the US as key to providing customers with local support and dedicated resources
aimed at the world's largest market."
As part of this expansion
Sistemic has made a number of new appointments including two additions to its
senior management team. Dr David Mallinson, who previously worked for Merck
Sharpe Dohme (MSD), joined the team on 1 May 2011 as a Senior Scientist and
will lead new projects at the expanded facility. Dr Max Bylesjo, who previously
worked for ALMAC group will join on 1 July 2011 as a Senior Bioinformatician
and will focus on continuing the development of Sistemic's unique data
processing technology. The company is currently seeking additional staff in
anticipation of continued growth.
The new Sistemic
headquarters will dedicate 60% of its space to new laboratory facilities,
equipped with state-of-the-art technology, and 40% as new commercial areas.
Sistemic has developed
unique analytical tools to enhance miRNA profiling turning it into a more
versatile problem solving technology. Sistemic products include: SistemRNA
TM
(core enabling platform) , SistemQC
TM (for cells, stem cells & cell therapy
markets), SistemTOX
TM (toxicity profiling) and SistemKB (knowledgebase
profiling). Example applications include screening of drug discovery lead
compounds to determine whole cell response to various chemistries as well as
cell characterization, QC monitoring, purity, potency and pluripotentcy assessment
of cell lines.
The company was founded in
2008 by a group of scientists including Professor Chris Hillier and Dr Vincent
O'Brien (currently CSO) who identified a unique opportunity to utilise miRNA
profiling, which forms their core IP. To date Sistemic has focused its efforts
on championing miRNA methodology to solve problems in the biotechnology, cell
therapeutics and drug discovery markets.
More information about the company's products and
services may be obtained at:
www.sistemic.co.uk
Sistemic,
SistemRNATM , SistemTOXTM, SistemKBTM and SistemQCTM are registered
trademarks of Sistemic Ltd.
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.